Senior Vice President and General Council · Travere Therapeutics, Inc. (TVTX)

Elizabeth Reed

A named executive officer of Travere Therapeutics in every fiscal year CompBrief holds from FY2018 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$2,018,708

Salary $468,417Stock awards $648,327

FY2022: $1,998,516

3rd of 6 named executive officers at Travere Therapeutics by FY2023 total.

6 named officers on file for Travere Therapeutics, FY2023

Elizabeth Reed’s pay file — $29

  • 6 fiscal years of pay, line by line
  • 9 equity grants, each cited to its filing
  • TVTX’s disclosed peer group of 16 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Travere Therapeutics’s whole pay program stands against its peers

  • Travere Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TVTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 27, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Elizabeth Reed’s full pay file as a PDF — free

More than this page: up to 10 years of Elizabeth’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Elizabeth Reed compensation by year

Travere Therapeutics Summary Compensation Table · all 6 fiscal years held
In US dollars, as Travere Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020FY2021FY2022FY2023
Salary$347,500$391,667$413,417$427,887$449,124$468,417
Bonus$0$0$0$0$0$0
Stock awards$391,180$215,520$432,880$403,200$761,200$648,327
Option awards$673,331$453,000$508,217$791,194$538,929$656,747
Non-equity incentive$161,000$187,500$235,463$257,094$236,775$230,300
Pension and deferred compensation$0$0$0$0$0$0
All other$8,250$10,760$11,214$11,696$12,488$14,917
Total$1,581,261$1,258,447$1,601,191$1,891,071$1,998,516$2,018,708

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Travere Therapeutics, Inc. DEF 14A filed March 27, 2024, accession 0001438533-24-000012, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Travere Therapeutics, Inc. filed document, accession 0001438533-24-000012. Every figure is read from that document and cited to the page and table it appears in. Filed March 27, 2024.

$1.6M
$1.3M
$1.6M
$1.9M
$2.0M
$2.0M
FY18
FY19
FY20
FY21
FY22
FY23
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU20,250$182,048—
RSU9,840$88,462—
RSU8,000$71,920—
RSU7,500$67,425—
RSU7,380$66,346—
RSU6,750$60,683—
RSU2,250$20,228—
Option1,146—$15.46
Option54,500—$22.40
Option20,500—$27.50
Option15,573—$26.88

Per the Outstanding Equity Awards at Fiscal Year-End table in Travere Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

56 Form 4 lines since the FY2023 proxy (filed March 27, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-09-15Sale10b5-1300$65.31105,389
2026-09-15Exercise or conversion10b5-137,500$15.46142,889
2026-09-15Sale10b5-121,926$62.03120,963
2026-09-15Sale10b5-11,400$63.69105,689
2026-09-15Sale10b5-113,874$62.63107,089
2026-09-15Exercise or conversion derivative10b5-137,500$0.000
2026-05-06Sale10b5-12,076$43.95105,211
2026-05-05Sale10b5-12,174$46.65107,287

The 8 most recent of 56 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Travere Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Eric DubePresident, Chief Executive Officer and Director$7,574,959
William RoteSenior Vice President and Head of Research and Development$2,053,099
Elizabeth Reed · this pageSenior Vice President and General Council$2,018,708
Peter HeermaChief Commercial Officer$2,003,914
Jula InrigChief Medical Officer$2,001,539
Christopher ClineChief Financial Officer$1,971,490

The full Travere Therapeutics compensation record

free company brief

This page is one person within Travere Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Travere Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Elizabeth Reed's compensation dossier · One-time report. No refunds.